Ibrutinib
- Generic Name
- Ibrutinib
- Brand Names
- Imbruvica
- Drug Type
- Small Molecule
- Chemical Formula
- C25H24N6O2
- CAS Number
- 936563-96-1
- Unique Ingredient Identifier
- 1X70OSD4VX
- Background
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell ...
- Indication
Ibrutinib is indicated for the treatment of the following conditions.
Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Waldenström's macroglobulinemia
Chronic graft-versus-host disease (cGVHD)
Mantle cell lymphoma (MCL)
Marginal zone lymphoma (MZL)
- Associated Conditions
- Chronic Graft-Versus-Host Disease, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma (MZL), Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Steroid-dependent chronic graft-versus-host disease, Waldenström's Macroglobulinemia (WM), Steroid refractory Chronic graft versus host disease
- Associated Therapies
- -
Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 1
- Registration Number
- NCT03679624
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML
- Conditions
- Interventions
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2018-08-22
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 122
- Registration Number
- NCT03642236
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2020-06-22
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Registration Number
- NCT03617484
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
- Conditions
- Interventions
- First Posted Date
- 2018-07-10
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT03581942
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited protocol Activities), Montvale, New Jersey, United States
Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT03535350
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2024-03-18
- Target Recruit Count
- 16
- Registration Number
- NCT03525925
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-05-02
- Last Posted Date
- 2024-11-28
- Target Recruit Count
- 5
- Registration Number
- NCT03514017
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations
- Conditions
- Interventions
- First Posted Date
- 2018-05-01
- Last Posted Date
- 2023-11-08
- Target Recruit Count
- 28
- Registration Number
- NCT03513562
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
- First Posted Date
- 2018-04-24
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 24
- Registration Number
- NCT03506373
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
- Conditions
- B-Cell Prolymphocytic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Lymphoplasmacytic LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Non-Hodgkin LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 18
- Registration Number
- NCT03479268
- Locations
- 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.